Literature DB >> 27698500

Arsenic Trioxide and Tretinoin (AsO/ATRA) for Acute Promyelocytic Leukemia (APL).

Erin Damery, Dominic A Solimando, J Aubrey Waddell.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2016        PMID： 27698500      PMCID： PMC5030872          DOI： 10.1310/hpj5108-628

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  14 in total

1.  Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Authors:  Elihu Estey; Guillermo Garcia-Manero; Alessandra Ferrajoli; Stefan Faderl; Srdan Verstovsek; Dan Jones; Hagop Kantarjian
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.

Authors:  Hong-Hu Zhu; De-Pei Wu; Jie Jin; Jian-Yong Li; Jun Ma; Jian-Xiang Wang; Hao Jiang; Sai-Juan Chen; Xiao-Jun Huang
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

Review 3.  Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Authors:  P J Hesketh; M G Kris; S M Grunberg; T Beck; J D Hainsworth; G Harker; M S Aapro; D Gandara; C M Lindley
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 4.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

5.  Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.

Authors:  Wing-Yan Au; Cyrus R Kumana; Harold K K Lee; Shek-Ying Lin; Herman Liu; Dominic Y M Yeung; June S M Lau; Yok-Lam Kwong
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

6.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

8.  Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.

Authors:  Chong-Wen Dai; Guang-Sen Zhang; Jian-Kai Shen; Wen-Li Zheng; Min-Fei Pei; Yun-Xiao Xu; Yi-Xiong Cao; Yan Yi; Jun-Jie Yang; Hong-Ling Peng; Hai-Ying Zhong; Rui-Juan Li
Journal:  Acta Haematol       Date:  2009-02-26       Impact factor: 2.195

9.  All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Authors:  Zhi-Xiang Shen; Zhan-Zhong Shi; Jing Fang; Bai-Wei Gu; Jun-Min Li; Yong-Mei Zhu; Jing-Yi Shi; Pei-Zheng Zheng; Hua Yan; Yuan-Fang Liu; Yu Chen; Yang Shen; Wen Wu; Wei Tang; Samuel Waxman; Hugues De Thé; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

10.  Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

Authors:  Emmanuel Raffoux; Philippe Rousselot; Jöel Poupon; Marie-Thérèse Daniel; Bruno Cassinat; Richard Delarue; Anne-Laure Taksin; Delphine Réa; Agnès Buzyn; Annick Tibi; Geneviève Lebbé; Patricia Cimerman; Christine Chomienne; Jean-Paul Fermand; Hugues de Thé; Laurent Degos; Olivier Hermine; Hervé Dombret
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544
View more
  1 in total

Review 1.  Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity.

Authors:  Alejandro Carazo; Kateřina Macáková; Kateřina Matoušová; Lenka Kujovská Krčmová; Michele Protti; Přemysl Mladěnka
Journal:  Nutrients       Date:  2021-05-18       Impact factor: 5.717
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.